The federal agency continues to keep researchers, pharma firms and citizens apprised of current happenings and research related to the virus and pandemic.
January 1, 2021 marked the UK’s official separation from the EU and with that has come a raft of changes to how the nation will now do business with the rest of the world.
Many issues around free trade and the movement of goods and services have been well documented but details of how this will affect IP in the UK have grabbed fewer headlines.
Nevertheless, this issue is highly relevant as IP can underpin the value of businesses, especially in the pharmaceutical industry.
The
EU-UK Trade and Cooperation Agreement, which came into effect on January 1, outlines the ongoing relationship between the UK and EU and governs trade between EU member states and the UK. The Agreement includes a number of provisions relating to the protection and enforcement of IP rights, and specifies that such rights will continue to be protected to at least the standards required by the international treaties that the UK and EU are both parties to. We comment on som
Continuus lands $69.3m US drug manufacturing contract The small-molecule pharmaceuticals manufacturer secured a DoD/HHS government contract to manufacture critical medicines for a range of conditions.
Continuus Pharmaceuticals, a firm that uses proprietary integrated continuous manufacturing (ICM) technology to manufacture drugs, has been granted a $69.3m (57 EUR) contract to manufacture three different medicines. The contract, awarded by the US Department of Defense (DoD) and Department of Health and Human Services (HHS), also will be used for construction of the country’s first GMP-certified facility for ICM-driven facility of small-molecule marketed drugs, generic medicines and investigational therapies, through all clinical trial phases and the rest of a product’s lifecycle.
Calyx spins off medical imaging, eClinical solutions firm Formerly Parexel Informatics, the renamed clinical research technology company has broken off and will operate as an independent company going forward.
Calyx a UK-based company offering medical imaging, eClinical and regulatory services to clinical research clients has shed the name Parexel Informatics in favor of its new moniker. After this strategic separation, the company will continue its work pursuing innovative technology intended to accelerate the discovery and development of new treatments.
With 250 new drug approvals in its history, Calyx has supported over 25,000 trials involving more than fourteen million patients. The company will continue its focus on providing innovative technology solutions and services to speed the discovery of new treatments.
Neurogene in tie up with university to advance gene therapy technologies New York based, Neurogene, has announced a research collaboration with the University of Edinburgh for the development of a multiple-platform approach to diseases not addressable by conventional gene therapy.
However, the partners were not willing to disclose, as of today, which diseases exactly are being targeted under this alliance.
The collaborative project combines Neurogene’s manufacturing and drug development capabilities with the University of Edinburgh’s novel platform and neurodevelopmental disease expertise.
Under the terms of the collaboration, the US company will provide financial support for Dr Stuart Cobb’s laboratory at the University of Edinburgh, in exchange for the right to license any applicable intellectual property at agreed-upon economic terms. Neurogene will be responsible for late stage preclinical and all clinical development of any products generat